Clinical Trial Update: Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke [Phase 3]

View source ↗

Summary

This update reports Phase 3 trial results assessing the safety and effectiveness of NXY-059 in patients who have suffered an acute stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• NXY-059 (NXY-059)

Snippet

Sponsor: AstraZeneca | Conditions: Cerebral Stroke, Stroke, Acute | Phase 3 | Status: COMPLETED